The AICAr compound regulates LRRK2 levels through ARE-mediated mRNA decay modulated by AUF1 binding and importantly AICAr treatment suppresses LRRK2 expression and rescues LRRK2-induced dopaminergic neurodegeneration and neuroinflammation in PD Drosophila and mouse models [80]. The gene discussed is LRRK2; the disease is Parkinson disease.